VBX-100 Prodrug Earns Orphan Drug Designation

Release Date: 19-Sep-2021

US FDA has granted Orphan Drug Designation to glycosylated cannabinoid prodrug VBX-100 for the treatment of patients with pediatric ulcerative colitis. Vitality Biopharma Inc, is looking forward to accelerate their research to improve safe and effective treatments for chronic disorders such as IBS and inflammatory diseases such as IBD, mainly ulcerative colitis in children. The company has developed over 100 novel cannabinoid compounds, including glycosylated tetrahydrocannabinol (THC) and water soluble glycosylated cannabidiol (CBD) prodrugs.


The FDA’s Orphan Drug Program provides financial incentives to companies developing drugs for rare diseases and conditions. Through the program, eligible drugs can be granted tax credits and other benefits.

Need custom market research solution? We can help you with that too.